ChronTech receives a six months’ extension of its option to buy back in ChronSeal®

As a consequence of that the results of the ChronSeal® study will not be made public until May 27th Kringle Inc. in Japan has given ChronTech Pharma a six months’ extension, i.e. until the 31st of December 2010, of its option to buy back in ownership of the ChronSeal®. For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail: anders.vahlne@ki.se About ChronTech ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.